Five decades of doxycycline: Does nanotechnology improve its properties?

Author(s)

Feitosa, Renata Carvalho ; Akioka Ishikawa, Elina Sawa ; Alves da Silva, Mariana Farias ; da Silva-Junior, Arnobio Antonio ; Oliveira-Nascimento, Laura

• Document type: Journal article
• Source: International Journal of Pharmaceutics; v. 618, p. 16-pg., 2022-04-25.

Abstract

Doxycycline (DX) is a well-established antimicrobial drug that has been used since 1967 to treat several diseases. This drug has a wide therapeutic range, acting as antibacterial, antiviral, antiparasitic, and anticancer agent, including its neuroprotective, anti-inflammatory, and wound healing effects. However, DX is unstable in the physiological environment, presenting poor cellular penetration and adverse effects related to gastrointestinal irritation. As for practically all antibiotics, bacteria can develop resistance to this drug. Pharmaceutical nano technology proved to be a promising strategy to overcome these drawbacks. Thus, this review addresses scientific studies regarding formulations of DX-loaded nanoparticles (DX-NPs) for therapy use. Formulations with different materials, manufacturing methods, and biomedical applications are described and discussed to understand NPs contribution for in vitro and in vivo DX performance. (AU)

• FAPESP's process: 20/08059-8 - Multifunctional molecule delivery to treat pulmonary infections and consequent local inflammation
• Grantee: Laura de Oliveira Nascimento
• Support Opportunities: Regular Research Grants
• FAPESP's process: 19/08281-5 - Development of biopolymeric wafers for buccal delivery of nanostructured drugs
• Grantee: Renata de Carvalho Feitosa
• Support Opportunities: Scholarships in Brazil - Master